The Cutting Efficiency of Hybrid Tips in Different Grades of Cataract
Cataract
Bottom Line
View on ClinicalTrials.gov: NCT05495555 ↗Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- INTREPID® Hybrid tip (Device)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Cataract and Laser Institute of Southern Oregon
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Phaco Time |
41.6; 41.8 | — |
| PRIMARY Aspiration Time |
101.7; 106.7 | — |
| PRIMARY Fluid Use |
41.6; 40.2 | — |
| SECONDARY Central Corneal Thickness Change From Baseline |
5.4; 8.1 | — |
Summary
Eligibility Criteria
Subjects are eligible for the study if they meet the following criteria:
Note: Ocular criteria must be met in both eyes.
- Be eligible to undergo sequential bilateral uncomplicated cataract surgery
- Grade 3 or 4 cataract (PNS or LOCS III)
- Undergo uneventful cataract surgery
- Gender: Males and Females.
- Age: 50 or older.
- Willing and able to provide written informed consent for participation in the study.
- Willing and able to comply with scheduled visits and other study procedures.
If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
- Patient under 50 years of age
- Unable to complete sequential bilateral cataract surgery in both eyes by the same surgeon (JS)
- Patient cataract surgery complicated by posterior capsular tear
- Any disease state deemed by PI that increases risk of complicated cataract surgery (ie Pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma. RA, prior refractive surgery, etc)
The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.
Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
Data sourced from ClinicalTrials.gov (NCT05495555). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.